Development of resistance to amphotericin B in Candida lusitaniae infecting a human.
Candida lusitaniae associated with infection in a patient with acute myelogenous leukemia developed resistance to amphotericin B during systemic treatment of the patient. The organism, when isolated initially, was inhibited by 0.31 mug of amphotericin B per ml in yeast nitrogen base agar, but when isolated (20 days later) just antemortem and postmortem, required 100 and 50 mug/ml, respectively, for complete inhibition at 48 h.
D000666:Amphotericin B / Q000627:therapeutic use*; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D008297:Male; D008875:Middle Aged
D000666:Amphotericin B